Predictors of remission of hyperprolactinaemia after long‐term withdrawal of cabergoline therapy
暂无分享,去创建一个
L. Cavallo | P. Cappabianca | A. Colao | G. Lombardi | S. Cirillo | A. di Sarno | E. Guerra | R. Pivonello | A. Elefante | F. Caranci | F. Briganti
[1] A. Colao,et al. Advances in the treatment of prolactinomas. , 2006, Endocrine reviews.
[2] A. Colao,et al. The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males , 2006, Clinical endocrinology.
[3] P. McEwan,et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. , 2004, Clinical endocrinology.
[4] A. Colao,et al. PRL Secreting Adenomas in Male Patients , 2005, Pituitary.
[5] P. Cappabianca,et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. , 2004, The Journal of clinical endocrinology and metabolism.
[6] G. Vitale,et al. Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. , 2004, The Journal of clinical endocrinology and metabolism.
[7] G. Krassas,et al. Cabergoline as a First-Line Treatment in Newly Diagnosed Macroprolactinomas , 2000, Pituitary.
[8] P. Cappabianca,et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. , 2004, The New England journal of medicine.
[9] P. Cappabianca,et al. Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia , 2003 .
[10] S. Corsello,et al. Giant prolactinomas in men: efficacy of cabergoline treatment , 2003, Clinical endocrinology.
[11] P. Cappabianca,et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. , 2003, European journal of endocrinology.
[12] M. Bronstein,et al. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. , 2002, The Journal of clinical endocrinology and metabolism.
[13] M. Losa,et al. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. , 2002, The Journal of clinical endocrinology and metabolism.
[14] P. Cappabianca,et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. , 2001, The Journal of clinical endocrinology and metabolism.
[15] J. Wass,et al. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia , 2001, Clinical endocrinology.
[16] D. Pauler,et al. Primary medical therapy of micro- and macroprolactinomas in men. , 2000, The Journal of clinical endocrinology and metabolism.
[17] P. Marzullo,et al. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas , 2000, Clinical endocrinology.
[18] P. Cappabianca,et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. , 2000, The Journal of clinical endocrinology and metabolism.
[19] C. Raftopoulos,et al. Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients , 2000 .
[20] C. Raftopoulos,et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. , 1999, The Journal of clinical endocrinology and metabolism.
[21] F. Trimarchi,et al. Cabergoline: A first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma , 1999, Journal of endocrinological investigation.
[22] G. Brabant,et al. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. , 1998, Clinical endocrinology.
[23] M. Cataldi,et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. , 1997, The Journal of clinical endocrinology and metabolism.
[24] M. Arosio,et al. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients , 1997, Journal of endocrinological investigation.
[25] J. Donckier,et al. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. , 1997, The Journal of clinical endocrinology and metabolism.
[26] A. Colao,et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. , 1997, The Journal of clinical endocrinology and metabolism.
[27] M. Vance,et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. , 1996, Journal of Clinical Endocrinology and Metabolism.
[28] J. Donckier,et al. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. , 1996, European journal of endocrinology.
[29] J. Webster,et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea , 1994, The New England journal of medicine.
[30] P. Maggioni,et al. Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. , 1992, European journal of obstetrics, gynecology, and reproductive biology.
[31] R. Croughs,et al. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. , 1991, Clinical endocrinology.
[32] R. Croughs,et al. Withdrawal of bromocriptine after long‐term therapy for macroprolactinomas; effect on plasma prolactin and tumour size , 1991 .
[33] B. Sherman,et al. The natural history of untreated hyperprolactinemia: a prospective analysis. , 1989, The Journal of clinical endocrinology and metabolism.
[34] M. Liu,et al. LONG‐TERM TREATMENT OF HYPERPROLACTINAEMIA WITH BROMOCRIPTINE: EFFECT OF DRUG WITHDRAWAL , 1987, Clinical endocrinology.
[35] J. Sheehan,et al. The natural history of untreated microprolactinomas. , 1987, Fertility and sterility.
[36] M. Esiri,et al. FACTORS IN THE OUTCOME OF TRANSSPHENOIDAL SURGERY FOR PROLACTINOMA AND NON‐FUNCTIONING PITUITARY TUMOUR, INCLUDING PREOPERATIVE BROMOCRIPTINE THERAPY , 1987, Clinical endocrinology.
[37] B. Sherman,et al. Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors. , 1986, The Journal of clinical endocrinology and metabolism.
[38] G. Faglia,et al. Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. , 1985, The Journal of clinical endocrinology and metabolism.
[39] D. Cook,et al. EFFECT OF DOPAMINE AGONIST WITHDRAWAL AFTER LONG-TERM THERAPY IN PROLACTINOMAS Studies with High-definition Computerised Tomography , 1984, The Lancet.
[40] M. Dudzinski,et al. Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors. , 1984, Fertility and sterility.
[41] D. Cook,et al. Hyperprolactinemia. Long-term effects of bromocriptine. , 1983, The American journal of medicine.
[42] A. Zarate,et al. Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. , 1983, Acta endocrinologica.
[43] L. Wide,et al. MENSTRUAL FUNCTION AND SERUM PROLACTIN LEVELS AFTER LONG‐TERM BROMOCRIPTINE TREATMENT OF HYPERPROLACTINAEMIC AMENORRHOEA , 1982, Clinical endocrinology.